A rational approach to the prevention and treatment of ARVI and influenza, as a medico-economic and socially significant problem of the XXI century

Close metadata

Recommended articles:

Minimally invasive interventions for complications associated with intra-abdominal calculi after laparoscopic cholecystectomy. Pirogov Russian Journal of Surgery. 2024;(5):14-20

The results of clinical application of the mesh with anti-adhesive fluoropolymer coating in laparoscopic intraperitoneal repair of primary ventral hernia. Pirogov Russian Journal of Surgery. 2024;(5):86-94

Reconstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reconstruction failure. P.A. Herzen Journal of Oncology. 2024;(3):13-19

Dynamics of morbidity and mortality from chronic non-communicable diseases in the Vladimir region. Russian Journal of Preventive Medicine. 2024;(6):49-52

Surgical treatment of traumatic arteriovenous fistulas of extremities. Pirogov Russian Journal of Surgery. 2024;(7):92-102

Morbidity of Psoriasis and psoriatic arthritis in the Republic of Bashkortostan in 2012—2022. Russian Journal of Preventive Medicine. 2024;(7):38-45

Role of acute kidney injury in the treatment of acute lower limb ischemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):457-462

Hypoalbuminemia as an independent predictor of complications, critical illness and premature death. Russian Journal of Anesthesiology and Reanimatology. 2024;(4):83-89

Prevalence and Risk Factors of Varicose Veins in the Yaroslavl Region. Journal of Venous Disorders. 2024;(3):232-245

Dynamics of the spectrum of genotypes of Listeria monocytogenes, which caused invasive listeriosis during the period of circulation of sars-cov-2 Omicron variants. Molecular Genetics, Microbiology and Virology. 2024;(3):29-36

Acute respiratory viral infections (ARVI) is a number of diseases mainly of the upper respiratory tract of viral etiology. ARVI occupy a leading place among all infectious diseases. The risk of developing complications can be up to 24%. There are measures to prevent complications: vaccination of the general population, for the treatment of the patient, the right choice of therapy is needed, that is, the appointment of etiotropic drugs aimed at stopping the replication of the virus. One of these medicines included in the clinical recommendations of the Ministry of Health of the Russian Federation is enisamia iodide. It has a direct antiviral effect, is active against a wide range of pathogens of ARVI and influenza. According to research, enisamia iodide helps to reduce the symptoms of the disease from the 2nd day of therapy, reduce the duration of the disease and prevent complications requiring additional antibiotic administration.

Keywords:

ARVI

influenza

morbidity

complications

vaccination

etiotropic therapy

symptoms

enisamy iodide

Authors:

Malyavin A.G.

Russian University of Medicine (Evdokimov Moscow State University of Medicine and Dentistry)

SPIN RSCI: 8264-5394
Scopus AuthorID: 6701876872
ORCID: 0000-0002-6128-5914

Received:

18.12.2024

Accepted:

13.02.2025

List of references:

Clinical recommendations of the Ministry of Health of the Russian Federation «Acute respiratory viral infections (ARVI) in adults». Approval year 2021. (In Russ.). Accessed December 12, 2024. https://cr.minzdrav.gov.ru/schema/724_1;
Sukhanov DS, Basina YuV, Alekseeva YuS, Timofeev EV. Optimization of the therapy of ARVI and influenza in outpatient practice. Lechashchij vrach. 2024;4:55-62. (In Russ.). https://doi.org/10.51793/OS.2024.27.4.008;
Zaitsev AA, Miroshnichenko NA, Ovchinnikov AYu, Nikolaeva YuO. Acute respiratory viral infections: Consensus on rational therapy. Consilium Medicum. 2024;26(9):575-578. (In Russ.). https://doi.org/10.26442/20751753.2024.9.202956
Slis’ SS, Kovalev EV, Yanovich EG, Kononenko AA, Noskov AK. The Main Risks of an Epidemic Emergency Associated with New Respiratory Viruses. Epidemiology and Vaccinal Prevention. 2022;21(2):7482. (In Russ.). https://doi.org/10.31631/2073-3046-2022-21-2-74-82
State report of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing «On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2023». M. 2024.
World Health Organization. Global report on infection prevention and control. Accessed December 12, 2024. https://www.who.int/publications/i/item/9789240051164
Balakrishnan VS. WHO’s first global infection prevention and control report. Lancet Infect Dis. 2022;22(8):1122. https://doi.org/10.1016/S1473-3099(22)00459-5;
Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus ADME. Influenza Vaccines: Successes and Continuing Challenges. J Infect Dis. 2021;224(12 Suppl 2):S405-S419. https://doi.org/10.1093/infdis/jiab269
Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. Antiviral Approaches against Influenza Virus. Clin Microbiol Rev. 2023;36(1):e0004022. https://doi.org/10.1128/cmr.00040-22
Sitnikov IG, Fazylov VKh, Silina EV. Treatment of influenza and other acute respiratory viral infections in patients with diabetes mellitus. Therapeutic Archive. 2019; 91(10):39-47. (In Russ.). https://doi.org/10.26442/00403660.2019.10.000333
Martynov AI, Malyavin AG, Zhuravleva MV, Bolieva LZ, Esaulenko EV, Babak SL, Kalyuzhin OV. Consensus of the Russian Scientific Medical Society of Therapists (RSMST) Expert Council «Improving Treatment Outcomes of Respiratory Tract Infections». Russian Journal of Preventive Medicine. 2019;22(4):144-151. (In Russ.). https://doi.org/10.17116/profmed201922041144;
Clinical recommendations of the Ministry of Health of the Russian Federation «Influenza in adults». Approval year 2022. (In Russ.). Accessed December 12, 2024. https://cr.minzdrav.gov.ru/schema/749_1
Orlova NV, Lomaychikov VV. Role of etiotropic therapy in the treatment and prevention of influenza complications amidst the COVID-19 pandemic. Meditsinskij sovet = Medical Council. 2021;18:86-93. (In Russ.). https://doi.org/10.21518/2079-701X-2021-18-86-93
Fischer WA 2nd, Gong M, Bhagwanjee S, Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart. 2014 Sep;9(3):325-336. https://doi.org/10.1016/j.gheart.2014.08.004
Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017 Sep;11(5):372-393. https://doi.org/10.1111/irv.12470
Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345-353. https://doi.org/10.1056/NEJMoa1702090;
Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, Timmis AD, Whitaker H, Smeeth L. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis. 2012;206(11):1652-1659. https://doi.org/10.1093/infdis/jis597
Boehme AK, Luna J, Kulick ER, Kamel H, Elkind MSV. Influenza-like illness as a trigger for ischemic stroke. Ann Clin Transl Neurol. 2018;5(4):456-463. https://doi.org/10.1002/acn3.545
Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016;1(3):274-281. https://doi.org/10.1001/jamacardio.2016.0433
World Health Organization. FluNet. Global Influenza Surveillance and Response System (GISRS). Accessed December 12, 2024. https://www.who.int/initiatives/global-influenza-surveillance-and-response-system
Maksakova VL, Erofeeva MK. Actual issues of influenza and ARVI prevention. Pharmateca. 2013;15(268):32-35. (In Russ.).
Report of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing «On the importance of influenza vaccination on the eve of the epidemiological season of acute respiratory infections and influenza». 2024.
World Health Organization. Global influenza strategy 2019-2030. Accessed December 12, 2024. https://iris.who.int/bitstream/handle/10665/311184/9789241515320-eng.pdf?sequence=18
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. Accessed December 12, 2024. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season
Kostinov MP, Zhang C, Khrapunova IA, Raicic SR, Pechenik AS, Utkin VA, Loktionova MN, Linok AV, Simonova EG, Brazhnik VA. Possible causes of morbidity and adverse outcomes of COVID-19 in vaccinated elderly patients. Journal Infectology. 2024;16(1):15-21. (In Russ.). https://doi.org/10.22625/2072-6732-2024-16-1-15-21
Kulakova NA, Protasov AD, Zhestkov AV, Kostinova TA. Vaccination against Viral Infections in Patients with Chronic Obstructive Pulmonary Disease (Literature Review). Epidemiology and Vaccinal Prevention. 2012;5(66):60-66. (In Russ.).
Priority vaccination of respiratory infections during the SARS-CoV-2 pandemic and after its completion. Kostinov MP, Chuchalin AG, eds. M.: MDV Group; 2020. (In Russ.).
Boytsov SA. Influenza, novel coronavirus infection and cardiovascular diseases. Russian Cardiology Bulletin. 2021;16(1):5-9. (In Russ.). https://doi.org/10.17116/Cardiobulletin2021160115
Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021;49(6):694-700. https://doi.org/10.1016/j.ajic.2021.02.012;
Sologub TV, Tokin II. Tactics of management of patients with influenza at the present stage. Effective Pharmacotherapy. 2017(10):14-19. (In Russ.).
Orlova NV, Kaminer DD. Comorbid patient with acute respiratory viral infections. Features of therapy and prevention. Medical Alphabet. 2019;1(9):8-12. (In Russ.). https://doi.org/10.33667/2078-5631-2019-1-9(384)-8-12
Zarubaev VV, Slita AV, Sinegubova EO, Muryleva AA, Lavrentieva IN. Anti-viral activity of enisamium iodide against viruses of influenza and ARVI’s on different cell lines. Therapeutic Archive. 2020;92(11):45-50. (In Russ.). https://doi.org/10.26442/00403660.2020.11.000872
Pshenichnaya NYu, Zhdanov KV, Lioznov DA. Final results of an adaptive randomized open-label controlled study on the efficacy and safety of enisamium iodide for inpatient treatment of the COVID-19 infection. Infectious Diseases. 2023;21(1):17-24. (In Russ.). https://doi.org/10.20953/1729-9225-2023-1-17-24
Walker AP, Fan H, Keown JR, Margitich V, Grimes JM, Fodor E, Te Velthuis AJW. Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases. bioRxiv [Preprint]. 2020 Jan;6: 2020.04.21.053017. https://doi.org/10.1101/2020.04.21.053017
Denisova AR, Maksimov ML. Acute respiratory viral infections: etiology, diagnosis, modern view of treatment. RMJ. Medical Review. 2018;1(II):99-103. (In Russ.).
Lioznov DA, Karnaukhova EJ, Zubkova TG, Shakhlanskaya EV. Evaluation of the effectiveness of ARVI treatment regimen includingetiotropic (enisamium iodide) and symptomatic treatment. Therapeutic Archive. 2020;92(3):50-55. (In Russ.). https://doi.org/10.26442/00403660.2020.03.000572
Gordienko VV, Kozlov KV, Shedey AA, Litvinov AA, Kasyanenko KV, Maltsev OV, Zhdanov KV. The efficacy and safety of enisamium iodide and umifenovir in the treatment of patients with acute respiratory viral infections in real clinical practice. Lechashchij vrach. 2024;1(27):49-55. (In Russ.). https://doi.org/10.51793/OS.2024.27.1.007
Metodicheskie rekomendatsii RNMOT «Diagnostika, profilaktika, lechenie i reabilitatsiya virusnogo porazheniya legkikh pri SARS-CoV-2 infektsii». Avdeev SN, Malyavin AG, eds. 2021. (In Russ.).
Order of the Ministry of Health of the Russian Federation dated March 18, 2024 No. 127n «On approval of the standard of medical care for adults with acute respiratory viral infections (ARVI) (diagnosis and treatment)». (In Russ.).

Close metadata